Patents by Inventor Kirk Robarge

Kirk Robarge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serine/threonine kinase inhibitors
    Patent number: 10519126
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 31, 2019
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20180127393
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: May 10, 2018
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Serine/threonine kinase inhibitors
    Patent number: 9708290
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: July 18, 2017
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • PIPERIDINE-DIONE DERIVATIVES
    Publication number: 20170001990
    Abstract: The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Jinhua CHEN, Charles Z. DING, Peter DRAGOVICH, Benjamin FAUBER, Zhenting GAO, Sharada S. LABADIE, Kwong Wah LAI, Hans Edward PURKEY, Kirk ROBARGE, Binqing WEI, Aihe ZHOU
  • Serine/threonine kinase inhibitors
    Patent number: 9388171
    Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: July 12, 2016
    Assignees: GENETECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20160122316
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Applicants: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Serine/threonine kinase inhibitors
    Patent number: 9259470
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 16, 2016
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140249127
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: February 14, 2014
    Publication date: September 4, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Serine/threonine kinase inhibitors
    Patent number: 8697715
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 15, 2014
    Assignees: Array BioPharma, Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140066453
    Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: August 27, 2013
    Publication date: March 6, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20130252934
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 26, 2013
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Serine Protease Inhibitors
    Publication number: 20070037813
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean Artis, Michael Dina, John Flygare, Richard Goldsmith, Regina Munroe, Alan Olivero, Richard Pastor, Thomas Rawson, Kirk Robarge, Daniel Sutherlin, Kenneth Weese, Aihe Zhou, Yan Zhu
  • Halo-alkoxycarbonyl prodrugs
    Patent number: 7109326
    Abstract: Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Alan G. Olivero, Kirk Robarge
  • Serine protease inhibitors
    Publication number: 20050186198
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 25, 2005
    Inventors: Ignacio Aliagas-Martin, Dean Artis, Michael Dina, John Flygare, Richard Goldsmith, Regina Munroe, Alan Olivero, Richard Pastor, Thomas Rawson, Kirk Robarge, Daniel Sutherlin, Kenneth Weese, Aihe Zhou, Yan Zhu
  • Novel halo-alkoxycarbonyl prodrugs
    Publication number: 20040220401
    Abstract: Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.
    Type: Application
    Filed: May 25, 2004
    Publication date: November 4, 2004
    Applicant: Genentech, Inc.
    Inventors: Brent Blackburn, Alan G. Olivero, Kirk Robarge
  • NOVEL HALO-ALKOXYCARBONYL PRODRUGS
    Publication number: 20010020019
    Abstract: Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.
    Type: Application
    Filed: April 14, 1998
    Publication date: September 6, 2001
    Applicant: GENENTECH, INC.
    Inventors: BRENT BLACKBURN, ALAN G. OLIVERO, KIRK ROBARGE
  • Tricyclic inhibitors of the vitronectin receptor
    Patent number: 5716951
    Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: February 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
  • Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
    Patent number: 5705890
    Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: January 6, 1998
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a
    Patent number: 5674865
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 7, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5674863
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 7, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge